Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study

C Ficorella; M F Morelli; E Ricevuto; K Cannita; G Porzio; P Lanfiuti Baldi; G Cianci; Z C DI Rocco; C Natoli; N Tinari; F DE Galitiis; F Calista; P Marchetti

doi:10.1038/sj.bjc.6601971

Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study

Br J Cancer. 2004 Aug 16;91(4):618-20. doi: 10.1038/sj.bjc.6601971.

Authors

C Ficorella¹, M F Morelli, E Ricevuto, K Cannita, G Porzio, P Lanfiuti Baldi, G Cianci, Z C DI Rocco, C Natoli, N Tinari, F DE Galitiis, F Calista, P Marchetti

Affiliation

¹ Medical Oncology, University of L'Aquila, Italy. ficorella@interfree.it

Abstract

A dose-finding study was undertaken to determine the maximum-tolerated dose, and the recommended dose of docetaxel in combination with 12-h timed (22:00-10:00) flat infusion of 5-fluorouracil (5-FU) in metastatic breast cancer patients. This schedule seems to reduce the occurrence of stomatitis of the docetaxel and infusional 5-FU regimen.

Publication types

Clinical Trial

MeSH terms

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*
Breast Neoplasms / pathology
Docetaxel
Drug Administration Schedule
Female
Fluorouracil / administration & dosage
Humans
Infusions, Intravenous
Maximum Tolerated Dose
Middle Aged
Neoplasm Metastasis
Taxoids / administration & dosage

Substances

Taxoids
Docetaxel
Fluorouracil